• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CDX
Click for more information
25.0% 15.0¢

CARDIEX LIMITED - Announcements

Market Cap $17.65M  ! watchlist Created with Sketch. Add to my watchlist

CardieX Limited is an Australia-based digital health technology company. The Company... CardieX Limited is an Australia-based digital health technology company. The Company develops and markets noninvasive patient monitoring technologies for assessing cardiovascular health. It specializes in the development of biomarkers and digital solutions for large-scale cardiovascular health disorders. Its solutions are designed to be deployed at point-of-care for arterial health screening, and as part of a remote patient monitoring regimen to extend care and enhance cardiovascular health outcomes. Its suite of products includes medical and home health devices and digital solutions for hypertension, cardiovascular disease, and other vascular health disorders all based on the Company’s SphygmoCor vascular biomarker technology. Its products include CONNEQT Pulse, SphygmoCor XCEL, and Oscar 2 Ambulatory Blood Pressure Monitor. CONNEQT Pulse measures both brachial and central blood pressures alongside a suite of vascular biomarkers to provide unparalleled insights into vascular health.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CDX CardieX China and Product Strategy Update - English12/03/19
CDX Appendix 3B06/03/19
CDX CardieX Announces Expansion of Bayer Pharma Trial ContractPRICE SENSITIVE06/03/19
CDX Appendix 4D Half Year ReportPRICE SENSITIVE28/02/19
CDX Half Year AccountsPRICE SENSITIVE28/02/19
CDX Transition of Directors & New Interim Chairman Appointment27/02/19
CDX Final Director's Interest Notice27/02/19
CDX Results of Extraordinary General Meeting26/02/19
CDX Senior Health Executive Appointed to Cardiex Advisory Board26/02/19
CDX Achievement of First CEO Performance Rights Hurdle21/02/19
CDX CardieX Technology Validated in Chinese Clinical Study04/02/19
CDX Transition of Chairman Role04/02/19
CDX CardieX Update on the Acquisition of 50.5% of inHealthPRICE SENSITIVE01/02/19
CDX CardieX Progress Summary & CEO Outlook30/01/19
CDX CardieX Despatches Notice of EGM to Shareholders25/01/19
CDX Notice of Extraordinary General Meeting/Proxy Form25/01/19
CDX Convertible Note Application Received from C2 VenturesPRICE SENSITIVE22/01/19
CDX Response to ASX Aware QueryPRICE SENSITIVE18/01/19
CDX Cardiex's inHealth Executes Major Co-Marketing AgreementPRICE SENSITIVE15/01/19
CDX Top 20 and Capital Structure14/01/19
CDX Top 20 Shareholders11/01/19
CDX Notice Under ASX Listing Rule 3.10.5A19/12/18
CDX Cleansing Notice Under s708A(5)(e)19/12/18
CDX CardieX's inHealth Signs LOI With Global Electronics CompanyPRICE SENSITIVE18/12/18
CDX Appendix 3B14/12/18
CDX CardieX Signs Agreement for Wearable Sensor DevelopmentPRICE SENSITIVE12/12/18
CDX CardieX Successfully Closes Oversubscribed $5.5m FundraisingPRICE SENSITIVE06/12/18
CDX Trading HaltPRICE SENSITIVE04/12/18
CDX Pause in TradingPRICE SENSITIVE04/12/18
CDX CEO Strategy Overview and 2019 PlanPRICE SENSITIVE03/12/18
CDX 2018 AGM Results30/11/18
CDX CardieX Owned inHealth Partners with Kaiser PermanentePRICE SENSITIVE28/11/18
CDX CardieX Corporate Update & Overview of inHealth TransactionPRICE SENSITIVE12/11/18
CDX 2018 Corporate Governance Statement07/11/18
CDX CardieX Partner Blumio Initiates Large Scale Clinical TrialPRICE SENSITIVE01/11/18
CDX CardieX 2018 Annual Report31/10/18
CDX Appendix 4G31/10/18
CDX Notice of 2018 Annual General Meeting/Proxy Form30/10/18
CDX New Medical Devices Supply Contract with AstraZenecaPRICE SENSITIVE26/10/18
CDX CardieX Subsidiary Wins New Medical Devices Supply ContractPRICE SENSITIVE26/10/18
CDX Audio Interview with CardieX CEO On inHealth Acquisition18/10/18
CDX Acquisition of Major Stake in inHealth MedicalPRICE SENSITIVE16/10/18
CDX Trading HaltPRICE SENSITIVE12/10/18
CDX Receipt of Subscription Proceeds from C2 Ventures Pty LtdPRICE SENSITIVE11/10/18
CDX CardieX Appendix 4E and 2018 Annual Financial StatementsPRICE SENSITIVE31/08/18
CDX Becoming a substantial holder29/08/18
CDX Appendix 3B28/08/18
CDX CardieX Investor Presentation17/08/18
CDX CardieX Reports Successful Trial Results for Wearable SensorPRICE SENSITIVE24/07/18 download Created with Sketch. 160.25KB
CDX Form 604 Change in substantial holding04/07/18 download Created with Sketch. 729.79KB
CDX CardieX Restructure and New Executive Appointments03/07/18 download Created with Sketch. 207.28KB
CDX CardieX Makes First Investment in Wearable Tech PartnershipPRICE SENSITIVE19/06/18 download Created with Sketch. 182.12KB
CDX CardieX Commences Trading Under New Code ASX.CDX18/06/18 download Created with Sketch. 107.67KB
CDX Appendix 3B15/06/18 download Created with Sketch. 476.35KB
CDX CardieX (AtCor) Entitlements Issue Heavily Over SubscribedPRICE SENSITIVE12/06/18 download Created with Sketch. 155.68KB
CDX Appendix 3Y - O'Dwyer05/06/18 download Created with Sketch. 269.95KB
CDX Appendix 3B05/06/18 download Created with Sketch. 475.22KB
CDX Appendix 3Y - Cooper01/06/18 download Created with Sketch. 213.13KB
CDX Appendix 3Y - Cairns01/06/18 download Created with Sketch. 212.4KB
CDX Appendix 3B01/06/18 download Created with Sketch. 455.22KB
CDX Revised Timing on Trade Commencement Under ASX.CDX31/05/18 download Created with Sketch. 114.04KB
CDX Change of Name to CardieX Limited & New Ticker ASX.CDX30/05/18 download Created with Sketch. 149.73KB
CDX Results of EGM28/05/18 download Created with Sketch. 218.71KB
CDX AtCor Announces Wearable Trial with Macquarie UniversityPRICE SENSITIVE21/05/18
CDX Blumio Wearable Cardio Trial with Macquarie UniversityPRICE SENSITIVE21/05/18
CDX Despatch of Underwritten Rights Issue Prospectus03/05/18
CDX Completion of Placement & Notice Under s708A01/05/18
CDX Appendix 3B - Completion of Placement01/05/18
CDX Notice of EGM and Proxy Despatched30/04/18
CDX Letter to Eligible Shareholders27/04/18
CDX Letter to Ineligible Shareholders27/04/18
CDX Appendix 3B - Entitlements Issue24/04/18
CDX Underwritten Rights Issue Prospectus Lodged with ASICPRICE SENSITIVE23/04/18
CDX Oversubscribed Capital Raising to Fast Track New StrategyPRICE SENSITIVE23/04/18
CDX Trading HaltPRICE SENSITIVE19/04/18
CDX Final Director's Interest Notice - D Brookes05/04/18
CDX Change to Board of Directors03/04/18
CDX Investor Presentation14/03/18
CDX AtCor Announces First Steps in Major Strategic RepositioningPRICE SENSITIVE14/03/18
CDX Resignation of CFO/Company Secretary06/03/18
CDX Half Yearly Report and AccountsPRICE SENSITIVE28/02/18
CDX AtCor's XCEL device clinically validated in 3rd party studyPRICE SENSITIVE23/01/18
CDX AtCor and PhysioAge Systems announce supply agreementPRICE SENSITIVE11/01/18
CDX Becoming a substantial holder22/12/17
CDX Final Director's Interest Notice21/12/17
CDX Initial Director's Interest Notice21/12/17
CDX Appointment of Niall Cairns as Non-Executive Director20/12/17
CDX AtCor secures $1.0 million new pharmaceutical trial contractPRICE SENSITIVE15/12/17
CDX Initial Director's Interest Notice05/12/17
CDX Final Director's Interest Notice05/12/17
CDX AtCor appoints Craig Cooper as CEOPRICE SENSITIVE30/11/17
CDX Results of Meeting30/11/17
CDX Chairman's address to 2017 AGMPRICE SENSITIVE30/11/17
CDX Craig Cooper to join AtCor board15/11/17
CDX Tax RefundPRICE SENSITIVE30/10/17
CDX Appendix 4G/Corporate Governance Statement27/10/17
CDX Annual Report to shareholders27/10/17
CDX Notice of Annual General Meeting/Proxy Form27/10/17
CDX Change of Director's Interest Notice x 329/09/17
CDX Appendix 3B22/09/17
CDX CardieX China and Product Strategy Update - English
12/03/19
CDX Appendix 3B
06/03/19
CDX CardieX Announces Expansion of Bayer Pharma Trial Contract
06/03/19PRICE SENSITIVE
CDX Appendix 4D Half Year Report
28/02/19PRICE SENSITIVE
CDX Half Year Accounts
28/02/19PRICE SENSITIVE
CDX Transition of Directors & New Interim Chairman Appointment
27/02/19
CDX Final Director's Interest Notice
27/02/19
CDX Results of Extraordinary General Meeting
26/02/19
CDX Senior Health Executive Appointed to Cardiex Advisory Board
26/02/19
CDX Achievement of First CEO Performance Rights Hurdle
21/02/19
CDX CardieX Technology Validated in Chinese Clinical Study
04/02/19
CDX Transition of Chairman Role
04/02/19
CDX CardieX Update on the Acquisition of 50.5% of inHealth
01/02/19PRICE SENSITIVE
CDX CardieX Progress Summary & CEO Outlook
30/01/19
CDX CardieX Despatches Notice of EGM to Shareholders
25/01/19
CDX Notice of Extraordinary General Meeting/Proxy Form
25/01/19
CDX Convertible Note Application Received from C2 Ventures
22/01/19PRICE SENSITIVE
CDX Response to ASX Aware Query
18/01/19PRICE SENSITIVE
CDX Cardiex's inHealth Executes Major Co-Marketing Agreement
15/01/19PRICE SENSITIVE
CDX Top 20 and Capital Structure
14/01/19
CDX Top 20 Shareholders
11/01/19
CDX Notice Under ASX Listing Rule 3.10.5A
19/12/18
CDX Cleansing Notice Under s708A(5)(e)
19/12/18
CDX CardieX's inHealth Signs LOI With Global Electronics Company
18/12/18PRICE SENSITIVE
CDX Appendix 3B
14/12/18
CDX CardieX Signs Agreement for Wearable Sensor Development
12/12/18PRICE SENSITIVE
CDX CardieX Successfully Closes Oversubscribed $5.5m Fundraising
06/12/18PRICE SENSITIVE
CDX Trading Halt
04/12/18PRICE SENSITIVE
CDX Pause in Trading
04/12/18PRICE SENSITIVE
CDX CEO Strategy Overview and 2019 Plan
03/12/18PRICE SENSITIVE
CDX 2018 AGM Results
30/11/18
CDX CardieX Owned inHealth Partners with Kaiser Permanente
28/11/18PRICE SENSITIVE
CDX CardieX Corporate Update & Overview of inHealth Transaction
12/11/18PRICE SENSITIVE
CDX 2018 Corporate Governance Statement
07/11/18
CDX CardieX Partner Blumio Initiates Large Scale Clinical Trial
01/11/18PRICE SENSITIVE
CDX CardieX 2018 Annual Report
31/10/18
CDX Appendix 4G
31/10/18
CDX Notice of 2018 Annual General Meeting/Proxy Form
30/10/18
CDX New Medical Devices Supply Contract with AstraZeneca
26/10/18PRICE SENSITIVE
CDX CardieX Subsidiary Wins New Medical Devices Supply Contract
26/10/18PRICE SENSITIVE
CDX Audio Interview with CardieX CEO On inHealth Acquisition
18/10/18
CDX Acquisition of Major Stake in inHealth Medical
16/10/18PRICE SENSITIVE
CDX Trading Halt
12/10/18PRICE SENSITIVE
CDX Receipt of Subscription Proceeds from C2 Ventures Pty Ltd
11/10/18PRICE SENSITIVE
CDX CardieX Appendix 4E and 2018 Annual Financial Statements
31/08/18PRICE SENSITIVE
CDX Becoming a substantial holder
29/08/18
CDX Appendix 3B
28/08/18
CDX CardieX Investor Presentation
17/08/18
CDX CardieX Reports Successful Trial Results for Wearable Sensor
24/07/18PRICE SENSITIVE download Created with Sketch. 160.25KB
CDX Form 604 Change in substantial holding
04/07/18 download Created with Sketch. 729.79KB
CDX CardieX Restructure and New Executive Appointments
03/07/18 download Created with Sketch. 207.28KB
CDX CardieX Makes First Investment in Wearable Tech Partnership
19/06/18PRICE SENSITIVE download Created with Sketch. 182.12KB
CDX CardieX Commences Trading Under New Code ASX.CDX
18/06/18 download Created with Sketch. 107.67KB
CDX Appendix 3B
15/06/18 download Created with Sketch. 476.35KB
CDX CardieX (AtCor) Entitlements Issue Heavily Over Subscribed
12/06/18PRICE SENSITIVE download Created with Sketch. 155.68KB
CDX Appendix 3Y - O'Dwyer
05/06/18 download Created with Sketch. 269.95KB
CDX Appendix 3B
05/06/18 download Created with Sketch. 475.22KB
CDX Appendix 3Y - Cooper
01/06/18 download Created with Sketch. 213.13KB
CDX Appendix 3Y - Cairns
01/06/18 download Created with Sketch. 212.4KB
CDX Appendix 3B
01/06/18 download Created with Sketch. 455.22KB
CDX Revised Timing on Trade Commencement Under ASX.CDX
31/05/18 download Created with Sketch. 114.04KB
CDX Change of Name to CardieX Limited & New Ticker ASX.CDX
30/05/18 download Created with Sketch. 149.73KB
CDX Results of EGM
28/05/18 download Created with Sketch. 218.71KB
CDX AtCor Announces Wearable Trial with Macquarie University
21/05/18PRICE SENSITIVE
CDX Blumio Wearable Cardio Trial with Macquarie University
21/05/18PRICE SENSITIVE
CDX Despatch of Underwritten Rights Issue Prospectus
03/05/18
CDX Completion of Placement & Notice Under s708A
01/05/18
CDX Appendix 3B - Completion of Placement
01/05/18
CDX Notice of EGM and Proxy Despatched
30/04/18
CDX Letter to Eligible Shareholders
27/04/18
CDX Letter to Ineligible Shareholders
27/04/18
CDX Appendix 3B - Entitlements Issue
24/04/18
CDX Underwritten Rights Issue Prospectus Lodged with ASIC
23/04/18PRICE SENSITIVE
CDX Oversubscribed Capital Raising to Fast Track New Strategy
23/04/18PRICE SENSITIVE
CDX Trading Halt
19/04/18PRICE SENSITIVE
CDX Final Director's Interest Notice - D Brookes
05/04/18
CDX Change to Board of Directors
03/04/18
CDX Investor Presentation
14/03/18
CDX AtCor Announces First Steps in Major Strategic Repositioning
14/03/18PRICE SENSITIVE
CDX Resignation of CFO/Company Secretary
06/03/18
CDX Half Yearly Report and Accounts
28/02/18PRICE SENSITIVE
CDX AtCor's XCEL device clinically validated in 3rd party study
23/01/18PRICE SENSITIVE
CDX AtCor and PhysioAge Systems announce supply agreement
11/01/18PRICE SENSITIVE
CDX Becoming a substantial holder
22/12/17
CDX Final Director's Interest Notice
21/12/17
CDX Initial Director's Interest Notice
21/12/17
CDX Appointment of Niall Cairns as Non-Executive Director
20/12/17
CDX AtCor secures $1.0 million new pharmaceutical trial contract
15/12/17PRICE SENSITIVE
CDX Initial Director's Interest Notice
05/12/17
CDX Final Director's Interest Notice
05/12/17
CDX AtCor appoints Craig Cooper as CEO
30/11/17PRICE SENSITIVE
CDX Results of Meeting
30/11/17
CDX Chairman's address to 2017 AGM
30/11/17PRICE SENSITIVE
CDX Craig Cooper to join AtCor board
15/11/17
CDX Tax Refund
30/10/17PRICE SENSITIVE
CDX Appendix 4G/Corporate Governance Statement
27/10/17
CDX Annual Report to shareholders
27/10/17
CDX Notice of Annual General Meeting/Proxy Form
27/10/17
CDX Change of Director's Interest Notice x 3
29/09/17
CDX Appendix 3B
22/09/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
15.0¢ 		Change
0.030(25.0%) 		Mkt cap ! $17.65M
Open High Low Value Volume
12.5¢ 15.5¢ 12.5¢ $109.5K 769.1K

Buyers (Bids)

No. Vol. Price($)
1 212 15.0¢
 

Sellers (Offers)

Price($) Vol. No.
15.5¢ 26442 2
View Market Depth
Last trade - 16.10pm 14/11/2024 (20 minute delay) ?
Last
14.5¢ 		  Change
0.030 ( 16.0 %)
Open High Low Volume
13.5¢ 15.5¢ 12.5¢ 141247
Last updated 15.27pm 14/11/2024 ?
CDX (ASX) Chart

Top Stories

ASX Market Open: Australia stocks track higher despite sluggish US performances after Fed comments | November 15, 2024

The ASX200 is set to open three quarters of a percent higher today despite US markets responding to comments from Jerome Powell
Yangibana 33% complete says Hastings, as it provides clarification on funding Hastings Technology Metals Ltd has provided an update on how development of the Yangibana project in Western Australia is progressing
Recce scores $6.75M R&D rebate Recce Pharmaceuticals (ASX: RCE) has received a cash refund of $6,751,176 Research and Development (R&D) Tax Incentive rebate from the Australian Taxation Office for FY24.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
HotCopper reacts as Resolute Mining told to pay US$160M if it wants its CEO back According to a report from Bloomberg, it appears Resolute Mining (ASX:RSG) CEO Terry Holohan is effectively being held ransom for US$160M.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.